Analysts Set Inspire Medical Systems, Inc. (NYSE:INSP) Price Target at $66.19

Shares of Inspire Medical Systems, Inc. (NYSE:INSP) have been given an average recommendation of “Hold” by the nineteen analysts that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $66.1875.

Several equities research analysts have weighed in on INSP shares. Evercore set a $54.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Weiss Ratings cut shares of Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday. Stifel Nicolaus set a $75.00 price objective on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. JPMorgan Chase & Co. increased their target price on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Finally, Zacks Research raised Inspire Medical Systems from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 17th.

Insider Buying and Selling

In other Inspire Medical Systems news, insider Jason Kelly sold 963 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. This trade represents a 4.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Inspire Medical Systems

Large investors have recently made changes to their positions in the business. Daiwa Securities Group Inc. raised its holdings in shares of Inspire Medical Systems by 38.7% during the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after acquiring an additional 130 shares in the last quarter. State of Wyoming boosted its holdings in Inspire Medical Systems by 31.5% in the fourth quarter. State of Wyoming now owns 731 shares of the company’s stock valued at $67,000 after acquiring an additional 175 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in Inspire Medical Systems by 84.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after acquiring an additional 205 shares in the last quarter. Apollon Wealth Management LLC boosted its holdings in Inspire Medical Systems by 5.6% in the first quarter. Apollon Wealth Management LLC now owns 3,997 shares of the company’s stock valued at $206,000 after acquiring an additional 212 shares in the last quarter. Finally, Blair William & Co. IL increased its position in Inspire Medical Systems by 5.1% during the 3rd quarter. Blair William & Co. IL now owns 4,865 shares of the company’s stock valued at $361,000 after purchasing an additional 234 shares during the period. 94.91% of the stock is currently owned by institutional investors.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $62.30 on Friday. The company has a market capitalization of $1.80 billion, a P/E ratio of 13.48, a PEG ratio of 4.79 and a beta of 0.70. Inspire Medical Systems has a fifty-two week low of $38.91 and a fifty-two week high of $147.03. The stock has a 50 day moving average price of $55.76 and a two-hundred day moving average price of $52.40.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm had revenue of $200.58 million for the quarter, compared to analysts’ expectations of $194.72 million. During the same quarter last year, the business earned $0.45 earnings per share. The business’s revenue was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities analysts predict that Inspire Medical Systems will post 1.24 earnings per share for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.